Snake venom peptide crotalicidin (Ctn) kills leukemia cells through dual membrane disruption and intracellular targeting, with 17-fold selectivity for tumor over healthy cells.
17-fold tumor selectivityCrotalicidin preferentially kills leukemia cells over healthy cells with dual membranolytic and intracellular mechanisms
What the researchers found
Ctn and Ctn[15-34] kill leukemia cells via dual membranolytic and intracellular mechanisms, with 17-fold and 7-fold tumor selectivity respectively, and protease stability up to 18-24 hours.
Why it matters
Cancer cells that resist conventional drugs may be vulnerable to membrane-disrupting venom peptides that bypass resistance mechanisms — and the high tumor selectivity reduces toxicity concerns.
The numbers in context
Selectivity: Ctn 17:1, Ctn[15-34] 7:1; serum stability up to 24h (Ctn) and 18h (fragment)
How the study worked
In-vitro study using flow cytometry, microscopy, and affinity purification proteomics to characterize antitumoral mechanisms and selectivity of Ctn and Ctn[15-34] against pro-monocytic leukemia cells.
Who was studied
THP-1 pro-monocytic leukemia cells and healthy cell controls
What this study cannot tell us
In-vitro study with one leukemia cell line; selectivity ratios may differ across cancer types; in-vivo efficacy and toxicity not tested; mechanism details need further validation.
How to read the evidence
Comprehensive in-vitro mechanistic study with proteomic target identification and selectivity quantification, but limited to one cancer cell line without in-vivo data.
When this study was published
Published in 2020; venom-derived anticancer peptides remain an active drug development area.
The bigger picture
This study shows venom peptides can be dual-action cancer killers — disrupting membranes AND targeting intracellular pathways — making them harder for cancer cells to resist.
Questions still open
- Does the dual mechanism prevent resistance development compared to single-mechanism drugs?
- Can Ctn selectivity be further improved by peptide engineering?
- How does Ctn perform in vivo against leukemia in animal models?
Common questions
Can snake venom fight cancer?
How does crotalicidin kill cancer cells?
Read the original research
Tumor Cell Attack by Crotalicidin (Ctn) and Its Fragment Ctn[15-34]: Insights into Their Dual Membranolytic and Intracellular Targeting Mechanism.
ACS chemical biology, 15(11), 2945-2957
Citation
Pérez-Peinado, Clara; Valle, Javier; Freire, João M; Andreu, David. (2020). Tumor Cell Attack by Crotalicidin (Ctn) and Its Fragment Ctn[15-34]: Insights into Their Dual Membranolytic and Intracellular Targeting Mechanism.. ACS chemical biology, 15(11), 2945-2957. https://doi.org/10.1021/acschembio.0c00596